Clinical trials: sponsored by Sun Pharmaceutical Industries Limited
Acne Vulgaris
A Study to Evaluate the Impact of Clascoterone 1% Cream on Skin Barrier Properties in Acne Prone Patients
Acne medications are a common source of facial dryness resulting in skin barrier damage and poor patient compliance. Retinoids and benzoyl peroxide are some of the most frequently prescribed and effective acne medications…
- Trial name
- NCT06415292
- Testing
- Winlevi (clascoterone) 1% cream
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Psoriatic Arthritis
Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab.
A long term study to demonstrate the safety of Tildrakizumab in Subjects with Psoriatic Arthritis who Have Previously Completed Study with Tildrakizumab
- Trial name
- NCT03552276
- Testing
- SUNPG18_07 I (Tildrakizumab 200 mg), SUNPG18_07 II (Tildrakizumab 100 mg)
- Where
- 66 sites in United States, Argentina and 6 more
- Volunteers
- 281 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Osteoarthritis of Knee
Efficacy and Safety of MM-II for Treatment of Knee Pain in Subjects With Symptomatic Knee Osteoarthritis
This is a phase IIb, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of MM-II in subjects with symptomatic knee OA as compared to matching placebo.
- Trial name
- NCT04506463
- Testing
- MM-II dose I, MM-II dose II, MM-II dose III
- Where
- 25 sites in United States, Denmark and 1 more
- Volunteers
- 397 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Dry Eye Disease
Effect of Cequa™ in Subjects With Dry Eye Disease
This is a Phase 4, multicenter, single arm, 12 week study in subjects with dry eye disease, which is inadequately controlled by cyclosporine 0.05% ophthalmic emulsion.
- Trial name
- NCT04357795
- Testing
- CequaTM (Cyclosporine 0.09%) ophthalmic solution
- Where
- 5 sites in United States
- Volunteers
- 135 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Primary Open Angle Glaucoma, Ocular Hypertension
A Therapeutic Equivalence Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
This is a randomized, Investigator-masked, multi-center, parallel group, therapeutic equivalence study with clinical endpoint.
- Trial name
- NCT05022004
- Testing
- Brinzolamide ophthalmic suspension, Azopt®
- Where
- 40 sites in India, Russia
- Volunteers
- 599 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Scalp Psoriasis
Efficacy and Safety of Tildrakizumab in the Treatment of Scalp Psoriasis
This is a multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of tildrakizumab in the treatment of moderate to severe psoriasis of the scalp.
- Trial name
- NCT03897088
- Testing
- PART 2: Double-blind Active Treatment Extension
- Where
- 25 sites in United States, Australia
- Volunteers
- 231 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Psoriasis
A Real World Study Evaluating the Long-Term Quality of Life of Tildrakizumab in Adult Patients With Psoriasis
This is a Phase 4 multicenter, uncontrolled open-label study design. There will be a total of 10 study visits at Screening, Baseline, Week 4, Week 8, Week 12, Week 16, Week 28, Week 40, Week 52 and Week 64, with subjects…
- Trial name
- NCT03718299
- Testing
- Injections of tildrakizumab
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Active Psoriatic Arthritis
Efficacy and Safety Study of SUNPG1623
This is a randomized, double-blind, placebo-controlled, multiple-dose, phase 2b study to demonstrate the safety and efficacy of SUNPG1623
- Trial name
- NCT02980692
- Testing
- SUNPG1623 I, SUNPG1623 II, SUNPG1623 III
- Where
- United States
- Volunteers
- 391 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Keratoconjunctivitis Sicca, Dry Eye Disease
Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
This is a Phase 2/3 study to evaluate the safety and efficacy of 2 different dose concentrations of OTX-101 dosed twice a day in both eyes for 84 days compared to placebo (vehicle) in patients with keratoconjunctivitis sicca (dry…
- Trial name
- NCT02254265
- Testing
- OTX-101 0.05%, OTX-101 0.09%, Vehicle
- Where
- United States
- Volunteers
- 455 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Keratoconjunctivitis Sicca
Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
This is a randomized, double-masked, vehicle-controlled study of the safety and efficacy of OTX-101 (0.09% cyclosporine nanomicellar solution) in the treatment of keratoconjunctivitis sicca to be conducted at approximately 50…
- Trial name
- Emerald (NCT02688556)
- Testing
- cyclosporine, vehicle of OTX-101
- Where
- 3 sites in United States
- Volunteers
- 745 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010)
This study is being conducted to evaluate the efficacy and safety/tolerability of subcutaneous tildrakizumab (MK-3222), followed by an optional long-term safety extension study, in participants with moderate-to-severe chronic…
- Trial name
- reSURFACE 1 (NCT01722331)
- Testing
- Tildrakizumab 200 mg, Tildrakizumab 100 mg
- Volunteers
- 772 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Plaque-type Psoriasis
A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous MK-3222 in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-012)
This study is being conducted to evaluate the efficacy and safety/tolerability of SCH 900222/MK-3222 in a population of participants with moderate-to-severe plaque psoriasis.
- Trial name
- NCT01936688
- Testing
- MK-3222 200 mg, MK-3222 100 mg, Etanercept 50 mg
- Sponsor
- Sun Pharmaceutical Industries Limited
Plaque Psoriasis
Evaluation of Adrenal Suppression Potential and Pharmacokinetics of Halobetasol Lotion 0.05%
The objective of this open-label multicentric study is to determine the adrenal suppression potential and the pharmacokinetic (PK) properties of halobetasol lotion (HBP) applied twice daily for up to two weeks in subjects aged 12…
- Trial name
- NCT03212963
- Testing
- Halobetasol Topical Lotion
- Where
- 3 sites in United States
- Volunteers
- 16 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Blepharoconjunctivitis
Comparative Study of AzaSite Plus Compared to AzaSite Alone and Dexamethasone Alone to Treat Subjects With Blepharoconjunctivitis
The purpose of this study is to determine if AzaSite Plus is effective and safe for the treatment of blepharoconjunctivitis compared to AzaSite alone and Dexamethasone alone.
- Trial name
- NCT00754949
- Testing
- 1% Azithromycin and 0.1% Dexamethasone, 1% Azithromycin, 0.1% Dexamethasone
- Sponsor
- Sun Pharmaceutical Industries Limited
Prostate Cancer
A Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to evaluate the serum testosterone levels in patients with Metastatic Castration-Resistant Prostate Cancer on SoluMatrix™ Abiraterone Acetate as Compared to Abiraterone Acetate
- Trial name
- STAAR (NCT02737332)
- Testing
- Zytiga® (Abiraterone Acetate), SoluMatrix™ (Abiraterone Acetate)
- Where
- 17 sites in United States
- Volunteers
- 53 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Open Angle Glaucoma, Ocular Hypertension
A Comparative Study of SPARC's SDP-133 Once Daily and Lumigan in Subjects With Open Angle Glaucoma or Ocular Hypertension
To evaluate the efficacy of once daily dosing with SPARC's novel ophthalmic formulation of bimatoprost compared with Lumigan 0.01% in subjects with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT03927443
- Testing
- SDP-133, Lumigan
- Sponsor
- Sun Pharmaceutical Industries Limited
Ocular Inflammation
Comparison Study of ISV-303 to Durasite Vehicle in Cataract Surgery Subjects
The purpose of this study is to evaluate the ocular safety, tolerability and efficacy of topical administration of ISV-303 compared with Durasite Vehicle.
- Trial name
- NCT01808547
- Testing
- ISV-303, DuraSite Vehicle
- Volunteers
- 268 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Keratoconjunctivitis Sicca
An Open-Label Extension of a Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
This is a safety extension enrolling subjects participating in Study OTX-101-2016-001 (NCT02688556)
- Trial name
- NCT02845674
- Testing
- OTX-101 0.09%
- Volunteers
- 258 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Inflammation and Pain Associated With Cataract Surgery
2nd Study to Assess ISV-305 Compared to Vehicle for Treatment of Inflammation and Pain Associated With Cataract Surgery
The purpose of this study is to evaluate the ocular safety, tolerability, and efficacy of ISV-305 (Dexamethasone in DuraSite® 2) compared to Vehicle in the treatment of inflammation and pain associated with cataract surgery.
- Trial name
- ISV-305 (NCT03192150)
- Testing
- ISV-305, Vehicle
- Where
- United States
- Volunteers
- 246 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Blepharoconjunctivitis
Comparative Study of AzaSite Plus Compared to AzaSite Alone and Dexamethasone Alone to Treat Subjects With Blepharoconjunctivitis
The purpose of this study is to determine if AzaSite Plus is effective and safe for the treatment of blepharoconjunctivitis compared to AzaSite alone and Dexamethasone alone.
- Trial name
- NCT00578955
- Testing
- 1% Azithromycin and 0.1% Dexamethasone, 1% Azithromycin, 0.1% Dexamethasone
- Volunteers
- 417 people
- Sponsor
- Sun Pharmaceutical Industries Limited